Investigation of Effects of Delayed Feedback on Non-motor Symptoms in Individuals With Parkinson's Disease

Parkinson Disease Clinical Trial

Official title:

Investigation of Effects of Delayed Feedback on Non-motor Symptoms in Individuals With Parkinson's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06217484
• Other study ID #: E-1228-23
• Status: Recruiting
• Start date: September 1, 2023
• Est. completion date: December 31, 2025

Study information

• Verified date: January 2024
• Source: Kessler Foundation
• Contact: Kai Sucich, MA
• Phone: 973-323-3693
• Email: ksucich[@]kesslerfoundation.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Learning deficits are frequent in individuals with Parkinson's Disease. Clear feedback is integral because through feedback individuals know whether they should stick with an action that they have been doing (if the feedback is positive), or change their course of action (if the feedback is negative). Learning though immediate feedback has been shown to be depended on the brain chemical dopamine that is disrupted in individuals with Parkinson's Disease. During learning, feedback can also be presented after a delay. The investigators propose that learning through delayed feedback will lead to greater learning in individuals with Parkinson's Disease, since learning through delayed feedback does not rely on dopamine. During the proposed paradigm, participants with Parkinson's Disease complete a multiple-choice test. After making their selection on the multiple-choice test, they either see feedback immediately or are given feedback 25 minute later after reviewing their selection on the multiple-choice test. The investigators hypothesize that participants will learn better when they are provided with delayed feedback.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: December 31, 2025
• Est. primary completion date: September 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• Only participants with scores above 24/30 on the Montreal Cognitive Assessment will be recruited for participation to exclude dementia.

Exclusion Criteria:

• Individuals with neurological conditions other than PD such as epilepsy, multiple sclerosis, brain tumors, etc. will be excluded to control for the effects these conditions have on the brain and behavior.

Related Conditions & MeSH terms

• Parkinson Disease

Intervention

Behavioral:
• delayed feedback
participants learn through either immediate or delayed feedback during a computer task

Locations

Country	Name	City	State
United States	Kessler Foundation	East Hanover	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Kessler Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent correct responses will be collected through the computer software	Response accuracy per trial	testing lasts 60 minutes and completed in 1 day